GeoVax Labs Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA

ATLANTA, Feb. 8 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the “Company”), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.